logo
Officials to test water from Ohio village near Cold War-era weapons plant after newspaper probe

Officials to test water from Ohio village near Cold War-era weapons plant after newspaper probe

CBS News27-04-2025
Authorities in Ohio plan to test the groundwater supply across a village near a former weapons plant after a newspaper investigation published Friday found high levels of radioactivity in samples taken at a school, athletic field, library and other sites.
The Army Corps of Engineers has been removing tons of contaminated soil from the Cold War-era site since 2018 and has long maintained that residential areas were not affected by the work.
However, The Blade in Toledo said its tests showed radioactivity levels 10 times higher than normal in water from a drinking fountain at Eastwood Middle School, 45 times higher than normal at the Luckey Library and 1,731 times higher than normal at a water pump near athletic fields.
"We've got to get to the bottom of this," said Lt. Col. Robert Burnham, commander of the U.S. Army Corps of Engineers' Buffalo District, which oversees the cleanup.
Nineteen of the 39 samples collected by the newspaper from well water across Luckey — at homes, businesses, and public places — showed radioactivity at least 10 times greater than what the federal government calls normal for the area, the newspaper said. The Blade hired an accredited private lab to conduct the testing.
The radioactivity detected was primarily bismuth-214, which decays from the radioactive gas radon-222. Experts agree that high levels of bismuth-214 suggest high radon levels are also present.
Radon exposure is the leading cause of lung cancer in nonsmokers.
The testing also found low levels of radioactive cobalt-60, a man-made isotope, in two wells. Experts called that finding extremely rare.
Taehyun Roh, a Texas A&M University scientist who specializes in environmental exposures, said regulators should also conduct air and soil testing to assess the extent of the contamination and identify the source.
"Since this area likely has high radon levels, testing for radon in both air and water is advisable," he wrote in an email. "A safe drinking water advisory should be issued, recommending the use of bottled water until further assessments and mitigation measures are in place."
The Corps of Engineers has long maintained that residential drinking water was not being contaminated by the removal work. Burnham and others said they still believe that to be true, citing thousands of their own soil samples.
The state Environmental Protection Agency and Department of Health will lead the testing. In an email, Ohio EPA spokesperson Katie Boyer told the newspaper the contaminant levels in the public drinking water are still "within acceptable drinking water standards." She said any concerns raised by the state testing would be addressed.
The 44-acre industrial site — 22 miles (35 kilometers) south of Toledo — was long crucial to America's nuclear weapons program. In the 1940s, farmland was replaced by a sprawling defense plant that produced magnesium metal for the Manhattan Project. In the 1950s, the plant became the government's sole source of beryllium metal for nuclear bombs, Cold War missiles and Space Race products, including a heat shield for Project Mercury.
"Things that happened generations ago are still affecting us," said Karina Hahn-Claydon, a 50-year-old teacher whose family lives less than a mile from the site. "And that's because the government didn't take care of it."
Private drinking wells, unlike municipal systems, are not regulated, and responsibility for testing is left to owners. The Blade's testing took place from April 2024 through January.
Radioactivity has been linked to an increased risk of various cancers, including blood and thyroid cancers.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

GoodRx (GDRX) Lifts Guidance as Pharma Partnerships Drive Double-Digit Growth
GoodRx (GDRX) Lifts Guidance as Pharma Partnerships Drive Double-Digit Growth

Yahoo

time3 hours ago

  • Yahoo

GoodRx (GDRX) Lifts Guidance as Pharma Partnerships Drive Double-Digit Growth

We recently published . GoodRx Holdings, Inc. (NASDAQ:GDRX) is one of the best healthcare stocks. GoodRx Holdings, Inc. (NASDAQ:GDRX) is a leading U.S. digital healthcare platform that helps consumers compare prescription drug prices and access discounts, while also expanding into telehealth and other healthcare services. A major recent focus is the company's growth in pharma manufacturer solutions, where it partners with drug makers for targeted advertising and patient access programs. In Q2 2025, revenue from this segment rose 32%, prompting GoodRx to raise its full-year growth forecast from 20% to 30%. This shift diversifies its business beyond traditional prescription savings cards and strengthens its role as a key marketing partner for pharmaceutical companies. Copyright: zneb076 / 123RF Stock Photo GoodRx Holdings, Inc. (NASDAQ:GDRX) is also broadening its consumer offerings through subscription-based services, including a new program for affordable erectile dysfunction medications (Sildenafil and Tadalafil). These initiatives support its mission of lowering out-of-pocket drug costs while enhancing direct-to-consumer healthcare access. Its telehealth platform remains an important but underutilized growth channel, with potential for further expansion. Additionally, GoodRx Holdings, Inc. (NASDAQ:GDRX) is undergoing a brand relaunch and implementing targeted marketing strategies to boost engagement and market share. While we acknowledge the potential of GDRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

LifeStance Health (LFST) Accelerates Growth with AI-Enabled Operations and Clinician Expansion
LifeStance Health (LFST) Accelerates Growth with AI-Enabled Operations and Clinician Expansion

Yahoo

time3 hours ago

  • Yahoo

LifeStance Health (LFST) Accelerates Growth with AI-Enabled Operations and Clinician Expansion

We recently published . LifeStance Health Group, Inc. (NASDAQ:LFST) is one of the best healthcare stocks. LifeStance Health Group, Inc. (NASDAQ:LFST) stands fifth among the best healthcare stocks. It is one of the largest outpatient mental health providers in the U.S. that operates over 550 locations across 33 states with nearly 7,500 clinicians, offering a hybrid of in-person and telehealth care (about 70% virtual). The company primarily serves patients with commercial insurance and focuses on expanding access to affordable behavioral health services. In 2025, LifeStance Health Group, Inc. (NASDAQ:LFST) accelerated its digital transformation, with a strong emphasis on artificial intelligence (AI) to improve efficiency. AI tools are being deployed in revenue cycle management, patient scheduling, and soon, clinician documentation, aimed at reducing administrative burdens and improving satisfaction. The appointment of Vaughn Paunovich as CTO marks a renewed push toward technology-driven operations. As part of this effort, the business is reviewing new electronic health record (EHR) platforms, with a decision expected by late 2025. Operational upgrades also include a digital patient check-in tool, improved HR and credentialing systems, and enhanced payer engagement platforms. These changes are designed to strengthen operational foundations for sustainable growth rather than rapid, acquisition-heavy expansion. Copyright: racorn / 123RF Stock Photo Q2 2025 saw an 11% increase in clinicians (173 added), supported by scheduling and productivity technologies that have improved retention and patient management. LifeStance Health Group, Inc. (NASDAQ:LFST) expects these digital and AI investments to yield significant productivity gains and improved patient care from 2026 onward, positioning the company as a leader in next-generation, tech-enabled mental health services. While we acknowledge the potential of LFST as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio

AbCellera Biologics (ABCL) Advances Proprietary Pipeline with Promising Phase 1 Trial Results
AbCellera Biologics (ABCL) Advances Proprietary Pipeline with Promising Phase 1 Trial Results

Yahoo

time3 hours ago

  • Yahoo

AbCellera Biologics (ABCL) Advances Proprietary Pipeline with Promising Phase 1 Trial Results

We recently published . AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the best healthcare stocks. AbCellera Biologics Inc. (NASDAQ:ABCL) is a biotech company specializing in discovering and developing therapeutic antibodies across various disease areas, including cancer, metabolic, endocrine, and autoimmune disorders. Their integrated platform combines technology, data science, and collaboration to identify promising antibody candidates. In recent developments, AbCellera Biologics Inc. (NASDAQ:ABCL) began dosing participants in a Phase 1 clinical trial for ABCL635, targeting vasomotor symptoms related to menopause, marking a key clinical milestone. The company reported strong Q2 2025 revenue growth, beating expectations and advancing both internal and partnered antibody programs despite ongoing net losses. Some analysts note that its innovative pipeline and expanding clinical presence could place it among the best healthcare stocks to watch in the biotech space. Photo by Myriam Zilles on Unsplash This Phase 1 trial signals the corporation's shift from primarily a discovery platform to a clinical-stage biotech with proprietary assets. Progress with ABCL635 addresses a significant unmet medical need and validates its platform's potential to develop first-in-class therapeutics. While we acknowledge the potential of ABCL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store